Study Details
A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants with Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Clinicaltrials.gov ID
Astellas Study ID
8951-CL-0103
EudraCT ID
2017-002566-50
Condition
Other, Stomach or Esophageal Cancer
Phase
Phase 2
Age
18 Years - N/A
Sex
Female & Male
Product
zolbetuximab
Type
Interventional
Trial Dates
Jun 2018 - Jul 2024
Masking
Double (Participant, Investigator)
Enrollment number
116
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy, in combination with mFOLFOX6 (with or without Nivolumab) and in Combination with Pembrolizumab in Subjects with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma whose Tumors have High or Intermediate Claudin (CLDN) 18.2 Expression
Study summary
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of Zolbetuximab (IMAB362) in Participants with Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site FR33002
Poitiers, France, 86021
Indiana University Cancer Center
Indianapolis, United States, 46077
Site IT39005
Milano, Italy
Memorial Sloan Kettering Cancer Center
New York, United States, 10065
Karmanos Cancer Institute
Detroit, United States, 48201
UCLA Medical Center
Santa Monica, United States, 90404
Site FR33003
Pessac, France, 33604
Site KR82002
Seongnam-si, Republic of Korea
Weill Cornell Medical College
New York, United States, 10065
Site IT39004
Padova, Italy
Site TW88602
Tainan, Taiwan, Province of China, 70403
Site TW88601
Taichung, Taiwan, Province of China
The Angeles Clinic and Research Institute
Los Angeles, United States, 90025
Site IT39003
Pisa, Italy
University of Chicago
Chicago, United States, 60637
Sanford Cancer Center
Sioux Falls, United States, 57104
Site FR33004
Paris, France, 75015
Site FR33001
Brest, France
Virginia Cancer Specialists
Fairfax, United States, 22031
Site KR82001
Seoul, Republic of Korea
Site IT39002
Napoli, Italy
Site JP81001
Chiba, Japan
Georgetown Univ Hospital
Washington, United States, 20007
Site JP81003
Tokyo, Japan
Site JP81002
Tokyo, Japan
Mass General / North Shore Can
Boston, United States, 02114